vs
CENTERSPACE（CSR）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
CENTERSPACE的季度营收约是MESA LABORATORIES INC的1.0倍（$66.6M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -27.7%，领先33.2%），MESA LABORATORIES INC同比增速更快（3.6% vs 0.3%），CENTERSPACE自由现金流更多（$64.3M vs $18.0M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 1.6%）
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CSR vs MLAB — 直观对比
营收规模更大
CSR
是对方的1.0倍
$65.1M
营收增速更快
MLAB
高出3.3%
0.3%
净利率更高
MLAB
高出33.2%
-27.7%
自由现金流更多
CSR
多$46.3M
$18.0M
两年增速更快
MLAB
近两年复合增速
1.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $66.6M | $65.1M |
| 净利润 | $-18.4M | $3.6M |
| 毛利率 | 96.5% | 64.2% |
| 营业利润率 | -15.9% | 12.2% |
| 净利率 | -27.7% | 5.6% |
| 营收同比 | 0.3% | 3.6% |
| 净利润同比 | -262.9% | 316.6% |
| 每股收益（稀释后） | $-1.08 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSRMLAB
| Q4 25 | $66.6M | $65.1M | ||
| Q3 25 | $71.4M | $60.7M | ||
| Q2 25 | $68.5M | $59.5M | ||
| Q1 25 | $67.1M | $62.1M | ||
| Q4 24 | $66.4M | $62.8M | ||
| Q3 24 | $65.0M | $57.8M | ||
| Q2 24 | $65.0M | $58.2M | ||
| Q1 24 | $64.5M | $58.9M |
净利润CSRMLAB
| Q4 25 | $-18.4M | $3.6M | ||
| Q3 25 | $53.8M | $2.5M | ||
| Q2 25 | $-14.5M | $4.7M | ||
| Q1 25 | $-3.7M | $-7.1M | ||
| Q4 24 | $-5.1M | $-1.7M | ||
| Q3 24 | $-1.0M | $3.4M | ||
| Q2 24 | $-1.3M | $3.4M | ||
| Q1 24 | $-3.9M | $-254.6M |
毛利率CSRMLAB
| Q4 25 | 96.5% | 64.2% | ||
| Q3 25 | 96.5% | 61.5% | ||
| Q2 25 | 96.5% | 62.0% | ||
| Q1 25 | 96.4% | 61.8% | ||
| Q4 24 | 96.5% | 63.3% | ||
| Q3 24 | 96.6% | 61.3% | ||
| Q2 24 | 96.6% | 64.0% | ||
| Q1 24 | 96.4% | 62.1% |
营业利润率CSRMLAB
| Q4 25 | -15.9% | 12.2% | ||
| Q3 25 | — | 7.8% | ||
| Q2 25 | -9.9% | 5.1% | ||
| Q1 25 | 7.1% | 2.4% | ||
| Q4 24 | 4.3% | 9.2% | ||
| Q3 24 | 9.8% | 6.1% | ||
| Q2 24 | 11.1% | 9.6% | ||
| Q1 24 | 6.3% | -460.6% |
净利率CSRMLAB
| Q4 25 | -27.7% | 5.6% | ||
| Q3 25 | 75.3% | 4.1% | ||
| Q2 25 | -21.2% | 8.0% | ||
| Q1 25 | -5.6% | -11.4% | ||
| Q4 24 | -7.6% | -2.7% | ||
| Q3 24 | -1.6% | 5.9% | ||
| Q2 24 | -2.0% | 5.8% | ||
| Q1 24 | -6.1% | -432.2% |
每股收益（稀释后）CSRMLAB
| Q4 25 | $-1.08 | $0.65 | ||
| Q3 25 | $3.19 | $0.45 | ||
| Q2 25 | $-0.87 | $0.85 | ||
| Q1 25 | $-0.22 | $-1.30 | ||
| Q4 24 | $-0.31 | $-0.31 | ||
| Q3 24 | $-0.40 | $0.63 | ||
| Q2 24 | $-0.19 | $0.62 | ||
| Q1 24 | $-0.37 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.8M | $29.0M |
| 总债务越低越好 | $1.0B | $68.4M |
| 股东权益账面价值 | $719.2M | $186.7M |
| 总资产 | $1.9B | $434.8M |
| 负债/权益比越低杠杆越低 | 1.42× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CSRMLAB
| Q4 25 | $12.8M | $29.0M | ||
| Q3 25 | $12.9M | $20.4M | ||
| Q2 25 | $12.4M | $21.3M | ||
| Q1 25 | $11.9M | $27.3M | ||
| Q4 24 | $12.0M | $27.3M | ||
| Q3 24 | $14.5M | $24.3M | ||
| Q2 24 | $14.3M | $28.5M | ||
| Q1 24 | $12.7M | $28.2M |
总债务CSRMLAB
| Q4 25 | $1.0B | $68.4M | ||
| Q3 25 | $1.1B | $69.4M | ||
| Q2 25 | $1.1B | $70.3M | ||
| Q1 25 | $955.5M | $71.3M | ||
| Q4 24 | $955.4M | $72.2M | ||
| Q3 24 | $921.3M | $73.1M | ||
| Q2 24 | $931.7M | $74.1M | ||
| Q1 24 | $929.1M | — |
股东权益CSRMLAB
| Q4 25 | $719.2M | $186.7M | ||
| Q3 25 | $748.6M | $178.5M | ||
| Q2 25 | $710.1M | $172.5M | ||
| Q1 25 | $636.8M | $159.8M | ||
| Q4 24 | $752.0M | $155.2M | ||
| Q3 24 | $672.5M | $161.5M | ||
| Q2 24 | $680.7M | $150.7M | ||
| Q1 24 | $688.1M | $145.4M |
总资产CSRMLAB
| Q4 25 | $1.9B | $434.8M | ||
| Q3 25 | $2.1B | $430.4M | ||
| Q2 25 | $2.0B | $435.7M | ||
| Q1 25 | $1.9B | $433.3M | ||
| Q4 24 | $1.9B | $433.3M | ||
| Q3 24 | $1.9B | $454.1M | ||
| Q2 24 | $1.9B | $440.4M | ||
| Q1 24 | $1.9B | $446.8M |
负债/权益比CSRMLAB
| Q4 25 | 1.42× | 0.37× | ||
| Q3 25 | 1.53× | 0.39× | ||
| Q2 25 | 1.57× | 0.41× | ||
| Q1 25 | 1.50× | 0.45× | ||
| Q4 24 | 1.27× | 0.47× | ||
| Q3 24 | 1.37× | 0.45× | ||
| Q2 24 | 1.37× | 0.49× | ||
| Q1 24 | 1.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $64.3M | $18.0M |
| 自由现金流率自由现金流/营收 | 96.5% | 27.7% |
| 资本支出强度资本支出/营收 | 51.3% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $125.9M | $37.9M |
8季度趋势，按日历期对齐
经营现金流CSRMLAB
| Q4 25 | $98.5M | $18.8M | ||
| Q3 25 | $35.1M | $8.2M | ||
| Q2 25 | $25.3M | $1.9M | ||
| Q1 25 | $25.4M | $12.7M | ||
| Q4 24 | $98.2M | $18.1M | ||
| Q3 24 | $32.3M | $5.3M | ||
| Q2 24 | $22.9M | $10.7M | ||
| Q1 24 | $24.4M | $12.9M |
自由现金流CSRMLAB
| Q4 25 | $64.3M | $18.0M | ||
| Q3 25 | $25.7M | $7.1M | ||
| Q2 25 | $15.5M | $884.0K | ||
| Q1 25 | $20.4M | $11.9M | ||
| Q4 24 | $41.6M | $17.3M | ||
| Q3 24 | $20.5M | $3.5M | ||
| Q2 24 | $9.1M | $9.9M | ||
| Q1 24 | $2.6M | $12.3M |
自由现金流率CSRMLAB
| Q4 25 | 96.5% | 27.7% | ||
| Q3 25 | 36.0% | 11.7% | ||
| Q2 25 | 22.7% | 1.5% | ||
| Q1 25 | 30.4% | 19.2% | ||
| Q4 24 | 62.6% | 27.6% | ||
| Q3 24 | 31.5% | 6.0% | ||
| Q2 24 | 14.0% | 16.9% | ||
| Q1 24 | 4.0% | 21.0% |
资本支出强度CSRMLAB
| Q4 25 | 51.3% | 1.1% | ||
| Q3 25 | 13.1% | 1.8% | ||
| Q2 25 | 14.2% | 1.7% | ||
| Q1 25 | 7.5% | 1.2% | ||
| Q4 24 | 85.3% | 1.3% | ||
| Q3 24 | 18.2% | 3.1% | ||
| Q2 24 | 21.2% | 1.5% | ||
| Q1 24 | 33.8% | 0.9% |
现金转化率CSRMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 0.65× | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSR
| Multi Family Residential | $57.3M | 86% |
| Other | $8.1M | 12% |
| Other Property Revenue | $1.2M | 2% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
